Skip to content
Riskpilot
← Back to search
Sign in
Get full access
ALDEN CANCER THERAPY AS
AS
Active
Org 912772438
Thormøhlens Gate 51, 5006
Bergen
Research and experimental development on natural sciences and engineering
· NACE 7210
Est. 2013
0 employees
Watchlist
Share
Norway
/
Companies
/
Research and experimental development on natural sciences and engineering
/
ALDEN CANCER THERAPY AS
Overview
Financials
People & ownership
Related companies
Loading company…
People & ownership
Management
Actively employed in the business
Name
Role
Member since
Current (1)
KH
Karl Henning Kalland
Chief Executive Officer
Chief Executive Officer
2013
Board of directors
Non-executive oversight
Name
Role
Member since
Current (3)
BT
Bjørn Tore Gjertsen
Deputy Chairman
2022
AM
Anne Margrete Øyan
Board of Directors
2022
AH
Anders Haugland
Chairman
2022
Former (2)
PK
Per-Odd Keul
Board of Directors
2020 – 2022
TO
Tor Ole Rognaldsen
Board of Directors
2022 – 2023
Shareholders
As of last annual report
Shareholder
Type
Ownership
Votes
Since
Yz Holding As
Company
58.93%
58.93%
2024
Vestlandets Innovasjonsselskap As
Company
30.36%
30.36%
2024
Oceanview Venture Capital As
Company
3.57%
3.57%
2024
Marck Invest As
Company
3.57%
3.57%
2024
Stener Kvinnsland
Individual
3.57%
3.57%
2024
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive.
Learn more
.
More on ALDEN CANCER THERAPY AS
Overview →
Headline figures, risk assessment and company summary
Financials & key figures →
Revenue, EBITDA, balance sheet and 5-year trend
Related companies →
Corporate hierarchy, parent and subsidiary network